1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 4,520 | 4,640 | 07:18 | |
| 4,520 | 4,640 | 06:51 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Di | Fortrea Holdings Inc: Fortrea und Emery Pharma kündigen strategische Zusammenarbeit zur Durchführung FDA-konformer Arzneimittelwechselwirkungsstudien mit Rifampin an | 242 | GlobeNewswire (Deutschland) | Die Zusammenarbeit ermöglicht die Prüfung von Nitrosamin-Verunreinigungen, so dass Sponsoren die akzeptable Verwendung von Rifampin in Arzneimittelwechselwirkungsstudien nachweisen könnenDurham, North... ► Artikel lesen | |
| Di | Fortrea Enters Strategic Collaboration With Emery Pharma | 2 | RTTNews | ||
| Di | Fortrea partners with Emery Pharma for rifampin impurity testing | 2 | Investing.com | ||
| Di | Fortrea Holdings Inc: Fortrea & Emery Pharma Announce Strategic Collaboration to Deliver FDA Compliant Drug-Drug-Interaction Studies Using Rifampin | 203 | GlobeNewswire (Europe) | Collaboration enables testing of nitrosamine impurities, allowing sponsors to demonstrate acceptable use of rifampin in drug-drug interaction studiesDURHAM, N.C., June 24, 2025(Nasdaq: FTRE) (the "Company")... ► Artikel lesen | |
| FORTREA Aktie jetzt für 0€ handeln | |||||
| 12.06. | Fortrea Holdings aktualisiert Anreizplan und Vorstandsmitglieder | 6 | Investing.com Deutsch | ||
| 12.06. | Fortrea stock rises after adopting poison pill as activists swirl | 7 | Investing.com | ||
| 12.06. | Fortrea Holdings Inc. - 8-A12B, Registration of securities | 2 | SEC Filings | ||
| 12.06. | Fortrea Holdings Inc: Fortrea Adopts Limited-Duration Stockholder Rights Plan | 1 | GlobeNewswire (USA) | ||
| 12.06. | Fortrea jumps 5% after naming Anshul Thakral as CEO | 2 | Seeking Alpha | ||
| 11.06. | Fortrea Appoints Anshul Thakral As CEO | - | RTTNews | ||
| 11.06. | Fortrea announces CEO appointment | 1 | Seeking Alpha | ||
| 11.06. | Fortrea Holdings Inc. - 8-K, Current Report | 10 | SEC Filings | ||
| 11.06. | Fortrea Holdings Inc: Fortrea Names Anshul Thakral Chief Executive Officer | 429 | GlobeNewswire (Europe) | DURHAM, N.C., June 11, 2025 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE) (the "Company"), a leading global contract research organization (CRO), today announced that Fortrea's Board of Directors (the... ► Artikel lesen | |
| 06.06. | Fortrea Holdings von S&P Global Ratings wegen schwacher Kennzahlen herabgestuft | 2 | Investing.com Deutsch | ||
| 06.06. | Fortrea Holdings downgraded to 'B-' by S&P Global Ratings due to weak credit metrics | 2 | Investing.com | ||
| 14.05. | Fortrea stock price target lowered to $8 by Mizuho | 4 | Investing.com | ||
| 13.05. | Beyond The Numbers: 6 Analysts Discuss Fortrea Holdings Stock | 8 | Benzinga.com | ||
| 12.05. | Fortrea Holdings Inc. - 10-Q, Quarterly Report | 3 | SEC Filings | ||
| 12.05. | Fortrea reaffirms $2.45B-$2.55B revenue guidance for 2025 as transformation efforts progress | 2 | Seeking Alpha | ||
| 12.05. | Fortrea Q1 2025 slides: $489M impairment charge overshadows EBITDA growth | 4 | Investing.com |
1 2 3 Weiter >>
52 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BB BIOTECH | 32,300 | +1,89 % | EQS-PVR: BB BIOTECH AG: Disclosure of Shareholdings | EQS Voting Rights Announcement: BB BIOTECH AG
Disclosure of Shareholdings
23.06.2025 / 07:00 CET/CEST
Dissemination of a Voting Rights Announcement... ► Artikel lesen | |
| QIAGEN | 40,370 | +0,40 % | Biotech Report: Evotec rutschen ab, auch Qiagen verlieren | (shareribs.com) Frankfurt 19.06.2025 - Biotech-Aktien bewegen sich im deutschen Handel überwiegend nach unten. Evotec korrigieren dabei um mehr als drei Prozent. An der Wall Street findet wegen eines... ► Artikel lesen | |
| NOVAVAX | 5,645 | +0,93 % | NOVAVAX INC - 8-K, Current Report | ||
| STRYKER | 334,00 | +0,30 % | Kurs der Stryker-Aktie verharrt auf Vortags-Niveau (324,7763 €) | Am US-amerikanischen Aktienmarkt ist die Stryker-Aktie aktuell unauffällig. Der jüngste Kurs betrug 374,99 US-Dollar. Die Wertschätzung der Börsenteilnehmer für die Aktie von Stryker hat sich heute... ► Artikel lesen | |
| ILLUMINA | 78,71 | -0,15 % | Standard BioTools Inc.: Standard BioTools Enters Next Phase of Transformation with Strategic Sale of SomaLogic to Illumina | Up To $425 Million In Total Proceeds Inclusive of Near-term Milestone Payments; $350 Million In Upfront Cash Retains Strategic Upside with Illumina Protein Prep Royalty Stream and Rights to Single... ► Artikel lesen | |
| CRISPR THERAPEUTICS | 40,400 | 0,00 % | CRISPR Therapeutics AG (CRSP): A Bull Case Theory | ||
| AAP IMPLANTATE | 1,440 | -1,37 % | EQS-AFR: aap Implantate AG: Vorabbekanntmachung über die Veröffentlichung von Finanzberichten gemäß §§ 114, 115, 117 WpHG | EQS Vorabbekanntmachung Finanzberichte: aap Implantate AG
/ Vorabbekanntmachung über die Veröffentlichung von Rechnungslegungsberichten
aap Implantate AG: Vorabbekanntmachung... ► Artikel lesen | |
| OCUGEN | 0,899 | +0,97 % | Ocugen, Inc.: Carisma Therapeutics and OrthoCellix Enter into Definitive Merger Agreement to Create Company Focused on Regenerative Cell Therapies for Orthopedic Diseases | Proposed reverse merger with OrthoCellix, a wholly-owned subsidiary of Ocugen, to create Nasdaq-listed, late clinical-stage regenerative cell therapy company with a first-in-class technology platform... ► Artikel lesen | |
| SANGAMO THERAPEUTICS | 0,465 | +3,56 % | Sangamo Therapeutics, Inc.: Sangamo Therapeutics Announces Positive Topline Results From Registrational STAAR Study in Fabry Disease | STAAR study demonstrated positive mean annualized estimated glomerular filtration rate (eGFR) slope at 52-weeks across all dosed patients in the study, which U.S. Food and Drug Administration (FDA)... ► Artikel lesen | |
| INTELLIA THERAPEUTICS | 8,414 | +2,24 % | Intellia Reports Positive 3-Year Lonvo-z Data in HAE Trial at EAACI Congress | ||
| SCORPIUS | 0,072 | 0,00 % | Scorpius Holdings, Inc. - 8-K, Current Report | ||
| EDITAS MEDICINE | 1,925 | -0,90 % | Editas Medicine, Inc.: Editas Medicine Reports Proprietary Targeted Lipid Nanoparticle Delivery in Non-Human Primates Enables In Vivo HBG1/2 Promoter Editing for Sickle Cell Disease and Beta Thalassemia at the European Hematology ... | Achieved 58% mean editing at five months after a single dose using high efficiency HSC delivery, demonstrating therapeutically relevant editing levels using a clinically validated strategy. Achievement... ► Artikel lesen | |
| DEFENCE THERAPEUTICS | 0,473 | +1,28 % | Defence Therapeutics Inc.: Defence Therapeutics Receives USPTO Allowance for Patent Application Covering Next-Gen ADC Technology | Montreal, Quebec--(Newsfile Corp. - June 9, 2025) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a leading biotechnology company specializing in drug... ► Artikel lesen | |
| BIOCRYST PHARMACEUTICALS | 8,388 | -1,87 % | BioCryst Pharmaceuticals, Inc.: BioCryst Achieves Reimbursement for ORLADEYO Across all Major European Countries | RESEARCH TRIANGLE PARK, N.C., June 06, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that, following a positive recommendation from the Zorginstituut Nederland... ► Artikel lesen | |
| KUROS BIOSCIENCES | 27,240 | -0,37 % | Laura Rosa ist neue Senior Vice President of Global Human Resources bei Kuros |
FORTREA HOLDINGS INC gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 4,520 Euro und damit -1,31 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu FORTREA HOLDINGS INC finden Sie auf Wallstreet Online.